US Patent

US8778393 — Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain

Method of Use · Assigned to AcelRx Pharmaceuticals Inc · Expires 2027-01-05 · 1y remaining

Vulnerability score 80/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects small volume oral transmucosal dosage forms containing sufentanil for the treatment of pain.

USPTO Abstract

Compositions, methods and systems for administration of small volume sufentanil-containing drug dosage forms to the oral mucosa of a subject are disclosed.

Drugs covered by this patent

sufentanil-citrate (SUFENTANIL CITRATE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1351`	—	sufentanil-citrate

Patent Metadata

Patent number: US8778393
Jurisdiction: US
Classification: Method of Use
Expires: 2027-01-05
Drug substance claim: No
Drug product claim: No
Assignee: AcelRx Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.